MYGN Stock Analysis: Buy, Sell, or Hold?
MYGN - Myriad Genetics Inc
$4.75
0.16 (3.49%)
▲
5d:
+2.81%
30d:
-10.04%
90d:
-22.76%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
MYGN is down 6.6% this week, but smart money is accumulating calls. Top strike: $3 2026-05-15 with 18 OI. Call ratio: 100% View Scanner →
Strength: 8.3/10
Get Alerted When MYGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MYGN trading at deep discount. Market pricing in -25.9% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: MYGN trading at deep discount. Market pricing in -25.9% annual earnings decline, creating value opportunity for patient investors.
In-depth Analysis How we analyze
Valuation Analysis: MYGN is currently trading at $4.75, which is considered oversold relative to its 30-day fair value range of $4.44 to $5.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 28.3) compared to its historical average (69.7). Remarkably, the market is currently pricing in an annual earnings decline of 25.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MYGN is in a strong downtrend. The price is approaching resistance at $4.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.78 (+63.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MYGN is in a strong downtrend. The price is approaching resistance at $4.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.78 (+63.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.44 -
$5.01
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 63.8% below Wall St target ($7.78)
Fair Price Analysis
30-Day Fair Range
$4.44 -
$5.01
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.20
Resistance Level
$4.88
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.29
Wall Street Target
$7.78
(+63.8%)
Revenue Growth (YoY)
-0.4%
Profit Margin
-44.4%
Valuation Discount vs History
-25.9% cheaper
PE vs Historical
28.3 vs 69.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.9%
(market-implied from PE analysis)
1-Year Target
$4.28
(-10%)
2-Year Target
$3.85
(-19%)
3-Year Target
$3.46
(-27%)
3-Yr Target (if PE normalizes)
(PE: 28→70)
$8.53
(+80%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.3, Growth: 193.0%)
$16.03
(+238%)
Base:
(SPY PE: 20.6, Growth: 193.0%)
$11.66
(+145%)
Bear:
(PE: 17.5, Growth: 193.0%)
$9.91
(+109%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.3 to 69.7
Stabilization Target:
$11.70
(+146.4%)
PE Expansion Potential:
+146.4%
Share & Embed Analysis
Last updated: April 02, 2026 10:34 PM ET
Data refreshes hourly during market hours. Next update: 11:34 PM
Data refreshes hourly during market hours. Next update: 11:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MYGN showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Samraat S Raha
BUY
40000 shares
2026-03-09
S. Louise Phanstiel
BUY
48000 shares
2026-02-27
S. Louise Phanstiel
BUY
50407 shares
2026-02-26
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 67 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 62 BUY |
Advanced MYGN Option Strategies
Professional options setups generated by AI based on today's MYGN price and gamma walls.
